Evidence map›Paper›PMID 28396255›Full record

ReviewProgress in neuro-psychopharmacology & biological psychiatry2017

The recent progress in animal models of depression.

Qingzhong Wang, Matthew A Timberlake, Kevin Prall, Yogesh Dwivedi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in neuro-psychopharmacology & biological psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qingzhong WangDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, SC711 Sparks Center, 1720 7th Ave South, Birmingham, AL, USA.
Matthew A TimberlakeDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, SC711 Sparks Center, 1720 7th Ave South, Birmingham, AL, USA.
Kevin PrallDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, SC711 Sparks Center, 1720 7th Ave South, Birmingham, AL, USA.
Yogesh DwivediDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, SC711 Sparks Center, 1720 7th Ave South, Birmingham, AL, USA. Electronic address: ydwivedi@uab.edu.

Funding

Plasma Exosomal MicroRNAs as Promising Novel Biomarkers for Suicidality and Treatment OutcomeR01MH107183 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DWIVEDI, YOGESH, SHELTON, RICHARD CHARLES · 2015 to 2019
$3.5M
MicroRNA Mapping in Major DepressionR01MH100616 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DWIVEDI, YOGESH · 2014 to 2019
$1.8M
Perturbed cell signaling network and suicide neurobiologyR01MH101890 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DWIVEDI, YOGESH · 2013 to 2017
$1.6M
Calcium Sensing Proteins in DepressionR01MH082802 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DWIVEDI, YOGESH · 2009 to 2013
$1.4M
Validating microRNA Analysis in Human Postmortem BrainR21MH081099 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DWIVEDI, YOGESH · 2007 to 2008
$384k
NIMH NIH HHS R01 MH082802NIMH NIH HHS R01 MH100616NIMH NIH HHS R01 MH101890NIMH NIH HHS R01 MH107183NIMH NIH HHS R21 MH081099
6 · The paper itself

Abstract

Major depression disorder (MDD) is a debilitating mental illness with significant morbidity and mortality. Despite the growing number of studies that have emerged, the precise underlying mechanisms of MDD remain unknown. When studying MDD, tissue samples like peripheral blood or post-mortem brain samples are used to elucidate underlying mechanisms. Unfortunately, there are many uncontrollable factors with such samples such as medication history, age, time after death before post-mortem tissue was collected, age, sex, race, and living conditions. Although these factors are critical, they introduce confounding variables that can influence the outcome profoundly. In this regard, animal models provide a crucial approach to examine neural circuitry and molecular and cellular pathways in a controlled environment. Further, manipulations with pharmacological agents and gene editing are accepted methods of studying depression in animal models, which is impossible to employ in human patient studies. Here, we have reviewed the most widely used animal models of depression and delineated the salient features of each model in terms of behavioral and neurobiological outcomes. We have also illustrated the current challenges in using these models and have suggested strategies to delineate the underlying mechanism associated with vulnerability or resilience to developing depression.

Indexed as

Disease Models, AnimalAnimalsBehavior, AnimalMajor Depressive DisorderBehaviorDepressionModelReviewRodents

Identifiers

PMID28396255
PMCPMC5605906

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.